Navigation Links
New ASCO/AUA guideline recommends men and their doctors discuss using 5-ARIs to reduce prostate cancer risk
Date:2/25/2009

ALEXANDRIA, Va. A newly released joint guideline produced by the American Society of Clinical Oncology (ASCO) and the American Urological Association (AUA) recommends that healthy men who are screened regularly for prostate cancer and show no symptoms of the disease should talk to their doctors about using a 5-alpha reductase inhibitor (5-ARI) to prevent the disease. 5-ARIs lower the level of the hormone dihydrotestosterone (DHT), which can contribute to the growth of prostate cancer.

This guideline aims to provide a useful tool for clinicians and their patients in making an informed decision about the potential benefits and risks of taking 5-ARIs for preventing prostate cancer and examines the use of 5-ARIs as a method of "chemoprevention" for prostate cancer. Chemoprevention is the use of a natural, synthetic or biologic substance to reverse, suppress or prevent the development of cancer. Currently, 5-ARIs are used to treat other non-cancerous conditions, such as male-pattern baldness and benign prostatic hyperplasia.

Prostate cancer is the most common non-skin cancer among men and the second-leading cause of cancer death in men. "Although one in every six men in the United States will be diagnosed with prostate cancer, we are not recommending that all men take 5-ARIs," said Barnett S. Kramer, MD, MPH, Associate Director for Disease Prevention at the National Institutes of Health and co-chair of the guideline panel. "However, we would encourage men to begin a dialogue with their doctors to determine if they could benefit from taking 5-ARIs to reduce their prostate cancer risk."

The key recommendations in the guideline include:

  • Men with a prostate-specific antigen (PSA) score of 3.0 or below who are screened regularly (or plan to get yearly PSA tests) and currently show no signs of prostate cancer are encouraged to talk with their doctor about the risks and benefits of taking a 5-ARI to further prevent their likelihood of getting prostate cancer

  • Men who are already taking a 5-ARI for other conditions should talk to their doctor about continuing to use this drug for the prevention of prostate cancer

The ASCO/AUA recommendations on chemoprevention for prostate cancer are based on evidence gathered from clinical trials, including the Prostate Cancer Prevention Trial (PCPT), in which participating men took a 5-ARI for one to seven years. Trial data showed an overall relative risk reduction of approximately 25 percent in most men who took a 5-ARI to prevent prostate cancer.

"Although a large clinical trial has shown that 5-ARIs can decrease the incidence of prostate cancer, we are still not able to determine if the mortality from prostate cancer is reduced," said Paul F. Schellhammer, MD, a past president of the AUA and co-chair of the panel that developed the guideline. "However, the demonstrated effect of 5-ARIs in reducing prostate cancer incidence makes it reasonable to recommend them for use to prevent the disease. But, as with any drug, patients should discuss the risks and benefits with their physicians."

In conjunction with this guideline, ASCO developed a Decision Aid Tool, which uses straightforward charts and diagrams to explain the risks and benefits of 5-ARIs to patients and their families. One section, called "Thinking It Over," encourages patients to discuss potential treatment decisions with their doctors and their family and determine what risks and benefits matter most to them.

The guideline will be published in the March issue of the Journal of Clinical Oncology and the March issue of The Journal of Urology. Along with the new guideline and the Decision Aid Tool, ASCO has released a corresponding patient guide available on ASCO's patient Web site, www.cancer.net.


'/>"/>

Contact: Lacey Dean
ldean@auanet.org
410-689-4054
American Urological Association
Source:Eurekalert

Related medicine news :

1. FDA Updates Prescription Guidelines for Blood Thinner
2. New Asthma Guidelines Stress Disease Control
3. Study finds primary care depression treatment often does not follow quality guidelines
4. New lung cancer guidelines oppose general CT screening
5. New Lung Cancer Guidelines Oppose General CT Screening
6. OSHA Issues Draft Ergonomics Guidelines on Preventing Musculoskeletal Injuries in Shipyards
7. Long-awaited international ethical guidelines for biobank researchers
8. Experts Publish New Lung Disease Guidelines
9. Heart Failure Society of America 11th Annual Scientific Meeting to Focus on Heart Failure Guidelines, Innovation and New Research
10. New guidelines set to improve standard of cows milk allergy care
11. GlycoMark Blood Test Included in Global Diabetes Care Guidelines as Emerging Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder ... of ElderCounsel, a national organization of elder law and special needs planning attorneys. “Membership ... rules. It also provides a forum to network with elder law attorneys nationwide,” said ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) ... a collection of specialty vendors and unique items from across the nation, this holiday-themed ... and wellness services offered by the VNA. The boutique will be open Saturday, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at ... of the most popular and least understood books in the Holy Scriptures, Revelation. The ... that have baffled scholars for centuries. Many have tossed it off as mere rubbish, ...
(Date:10/13/2017)... ... ... Journey: From the Mountains to the Mission Field”: the story of a missionary couple ... From the Mountains to the Mission Field” is the creation of published author, Carole ... and currently teaches a class of ladies at her church, which she has taught ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... LAWRENCE, Mass. , Oct. 4, 2017 /PRNewswire/ ... developer of single-use, self-contained, illuminating medical devices, today ... National Health Surveillance Agency (or Agência Nacional ... ®. The first single-use, cordless surgical retractor with ... ONETRAC provides optimal access, illumination and exposure of ...
(Date:10/2/2017)... The Rebound mobile app is poised to become a vital ... prescription drug addiction. The app empowers users to develop an ... their dosage in a safe, controlled manner while maximizing well-being. ... 100,000 people to sign up will enjoy 3 months of ... ...
(Date:9/25/2017)... AMSTERDAM , Sept. 25, 2017   ... Trial Master File solutions, today—from the IQPC Trial ... Amsterdam , NL)—announced that EastHORN Clinical Services ... its clinical programs and TMF management. EastHORN, a ... Montrium,s eTMF platform to increase transparency to enable ...
Breaking Medicine Technology: